NCT03237780 2026-03-18Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting72 enrolled